Viewing Study NCT04807166

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:08 PM
Ignite Modification Date: 2026-06-16 @ 7:41 PM
Study NCT ID: NCT04807166
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-07-03
First Post: 2021-03-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Sponsor: Wenjun Cheng
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Neoplasms View
None Fallopian Tube Neoplasms View
None Neoplasms by Site View
None Genital Neoplasms, Female View
None Neoplasms, Glandular and Epithelial View
None Neoplasms by Histologic Type View
None Carcinoma, Ovarian Epithelial View
None Ovarian Diseases View
None Genital Diseases, Female View
None Endocrine System Diseases View
None Carcinoma View
None Anlotinib View
None Angiogenesis View
None Antineoplastic Agents View
None Tyrosine Kinase Inhibitor View
Keywords:

Keywords

Keyword Brief Keyword Text View
None First-line treatment View
None Advanced Ovarian Cancer View
None Anlotinib View
None Carboplatin/Paclitaxel View
None Efficacy and Safety View